The problem isn't the idea — it's the design
Every operating partner covering a cluster of B2B software portcos eventually asks the same question: how do I get GTM leverage across the portfolio without building a bureaucracy that founders route around? The question is urgent now. PE exit volume has hit its lowest quarterly level since Q1 2024, with 13,509 PE-backed companies in backlog and only premium assets clearing at scale. More than 84% of PE fund managers report longer hold periods, with LPs demanding crisp value creation plan execution — not a slide deck of intentions. A commercial center of excellence, designed correctly, is how GTM stops being the least-instrumented function in your portfolio and starts becoming a board-defensible operating capability.
What a CoE actually owns versus what stays local
The failure mode is treating the CoE as a shared services bureau — a pool of people who do GTM work for portcos on request. Founders ignore it because it competes with their autonomy and rarely moves fast enough to matter.
The working model inverts that. The CoE owns the instruments and the standards. Each portco owns the execution.
Concretely, the CoE is accountable for:
- A common diagnostic layer. A Revenue Readiness Index or equivalent — a scored assessment that makes GTM health comparable across holdings. Without this, every board review is a different language. With it, you can rank portcos by commercial risk and prioritize intervention before a quarter goes sideways.
- ICP and persona libraries. Not generic personas — structured definitions that travel across the portfolio, get updated as markets shift, and survive leadership turnover. When a new CRO joins a portco, they inherit a working artifact, not a blank whiteboard.
- Value-creation roadmaps with named milestones. The CoE sets the framework; portco leadership owns the timeline and the numbers. This is what makes GTM legible to a board or LP — not a narrative, a structured plan with observable checkpoints.
- Diligence and exit prep standards. Documented AI programmes now command measurable premiums in PE due diligence. The CoE defines what "documented" means and ensures portcos accumulate that evidence systematically, not in a scramble six months before a process.
What stays local: pipeline management, hiring, comp design, campaign execution, and any GTM motion that is specific to a portco's segment or buyer. The CoE does not run sales for anyone.
Who owns it — and why that decision determines whether it works
Ownership structure is where most CoEs die quietly. Three patterns exist:
Firm-side ownership. An operating partner or dedicated commercial VP sits at the fund level, sets standards, and has explicit authority to require portcos to participate in diagnostics and reporting. This works when the operating partner has credibility with founders — meaning they have run revenue, not just advised on it.
Embedded rotation model. Functional leads spend defined time across portcos, building the instruments locally and leaving them behind. Higher cost, higher adoption. Works well when portcos are at different maturity stages and need more hands-on calibration.
Third-party anchor. An external partner holds the methodology and instruments; portco engagement is structured through the operating partner. This keeps the CoE lean and avoids the political problem of fund-side staff being perceived as oversight rather than support.
The hybrid that survives: firm-side ownership of standards and diagnostics, external or embedded execution support, and portco leadership accountable for named milestones on the value-creation roadmap. The operating partner is the connective tissue, not the delivery mechanism.
The comparability problem — and why it is now an exit-multiple problem
Here is the uncomfortable truth most CoE designs miss: the value of a commercial center of excellence is not operational efficiency. It is comparability.
When your eight portcos all report pipeline health in different formats, with different definitions of a qualified opportunity, different NRR calculations, and different ICP assumptions, you cannot make a credible argument to an acquirer or LP that the portfolio has a commercial operating model. You have eight individual stories. Individual stories compress multiples.
This matters more than it did two years ago. AI-native SaaS companies are showing median NRR in the 48–49% range — a hidden diligence risk that buyers are now actively probing. If your portcos cannot surface clean retention data in a consistent format, that risk gets priced in conservatively. The CoE's diagnostic layer is what makes the data defensible, not just available.
What this means for operating partners
Four concrete moves, in sequence:
- Start with a diagnostic, not a program. Before you design the CoE, run a Revenue Readiness assessment across your eight portcos. Rank them. Identify the two or three with the most acute GTM risk. The CoE earns credibility by solving a visible problem, not by announcing a new structure.
- Define what "comparable" means before your next board cycle. Agree on a short list of GTM metrics — pipeline coverage, NRR, ICP fit rate, sales cycle length — that will be reported in the same format across all holdings. This is the minimum viable CoE output.
- Separate the instruments from the people. The CoE's durability comes from named artifacts — the index, the ICP library, the roadmap template — not from specific individuals. Leadership turnover is inevitable. The instruments survive it; people do not.
- Tie CoE participation to value-creation plan milestones, not to enthusiasm. Founders engage with things that are connected to their incentive structure. If the CoE's diagnostic output informs the board's view of management performance, participation is not optional.
FAQ
How do PE firms prevent a commercial CoE from becoming overhead that portcos ignore?
The CoE fails when it produces programs instead of instruments. Founders ignore programs because they feel like corporate overhead. They use instruments — a scored diagnostic, a structured ICP library, a value-creation roadmap — because those artifacts make their own performance more legible to the board and reduce the cost of onboarding new commercial leadership. Tie the instruments to the incentive structure and the adoption problem largely solves itself.
What should a commercial CoE own versus what should stay at the portco level?
The CoE owns the standards, diagnostics, and shared methodology — the things that make GTM health comparable across holdings and defensible in a diligence process. Portcos own execution: pipeline management, hiring, campaign decisions, and anything specific to their buyer and segment. The moment the CoE starts running GTM for portcos, it becomes a bureaucracy.
Why does GTM comparability matter for exit multiples?
Acquirers and secondary buyers are pricing commercial risk. If each portco reports GTM health in a different format with different definitions, the portfolio looks like a collection of individual bets, not a managed operating model. With exit volume compressed and a large backlog of PE-backed companies competing for buyer attention, assets that can demonstrate a documented, consistent commercial operating model command a premium. The CoE's diagnostic layer is what makes that demonstration credible.